NASDAQ:CMRX - Chimerix, Inc.
$1.99
 $0.02
+1.02%
2:30PM EDT
2019-02-15
Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CMRX     avg for
industry  
  avg for
sector  
42 stocks weight:  32. 61   0. 01   3. 19  
42 stocks rank:  3. 26 K 2. 01 K 1. 09 K
# analyst opinions:  5. 00   14. 84   14. 43  

quick ratio:  19. 57   5. 33   1. 80  
current ratio:  19. 89   5. 64   2. 19  

target price low:  3. 18   89. 87   116. 44  
target price avg:  4. 00   116. 13   140. 62  
target price high:  6. 25   144. 13   161. 60  
1-yr high:  5. 90   124. 91   142. 18  
last close:  2. 25   101. 33   125. 34  
50-day avg:  2. 76   98. 45   122. 34  
200-day avg:  3. 84   99. 87   122. 31  
1-yr low:  2. 12   77. 93   99. 86  
volume:  256. 70 K 2. 40 M 4. 39 M
50-day avg volume:  304. 10 K 3. 29 M 4. 86 M
200-day avg volume:  212. 99 K 3. 21 M 4. 16 M

1-day return:  2. 27 % 0. 35 % -0. 08 %
this week return:  2. 27 % 0. 46 % -0. 07 %
12-wk return:  -31. 19 % 5. 59 % 1. 56 %
52-wk return:  -56. 56 % -0. 88 % 14. 91 %

enterprise value (EV):  -75. 66 M 54. 52 B 102. 18 B
market cap:  114. 13 M 48. 30 B 93. 12 B
EBITDA:  -73. 92 M 4. 78 B 7. 07 B
enterprise multiple (EV/EBITDA):  1. 02   -88. 47   2. 58  
enterprise/revenue (EV/R):  -18. 03   30. 50   23. 55  
total revenue:  4. 20 M 11. 17 B 39. 03 B
total debt:  167. 00 K 13. 63 B 16. 46 B
debt/equity:  0. 09   255. 18   110. 71  
net income (common):  -73. 76 M 2. 34 B 3. 51 B

shares outstanding:  50. 72 M 601. 87 M 1. 19 B
shares:  39. 03 M 599. 22 M 1. 12 B
shares short:  430. 15 K 11. 51 M 12. 17 M
shares short prior month:  623. 80 K 11. 81 M 13. 15 M
short ratio:  0. 98   4. 63   2. 90  
short % of float:  1. 17 % 6. 17 % 2. 78 %
total cash/share:  3. 62   12. 23   11. 30  
total cash:  183. 36 M 7. 42 B 7. 19 B
free cash flow:  -31. 97 M 94. 45 M 2. 03 B
operating cash flow:  -57. 55 M 161. 90 M 3. 01 B

book value:  3. 74   14. 36   28. 94  
price/book:  0. 60   -1. 54   -2. 98  
gross profits:  -44. 95 M 8. 20 B 15. 98 B
operating margins:  -1784. 39 % -468. 22 % -616. 90 %
EBITDA margins:  0. 00 % 13. 04 % 22. 45 %
profit margins:  0. 00 % 6. 01 % 9. 83 %
gross margins:  0. 00 % 48. 26 % 54. 52 %

1-yr max volatility:  11. 68 % --- ---
1-yr mean volatility:  -0. 27 % 0. 02 % 0. 07 %

1-yr EPS:  -1. 54   2. 91   4. 09  
forward EPS:  -1. 49   4. 19   6. 88  
P/E:  -1. 46   4. 76   27. 05  
forward P/E:  -1. 48   7. 25   10. 02  
PE/G:  0. 02   1. 60   5. 54  
growth:  -58. 90 % 630. 40 % 97. 64 %
earnings high:  -0. 31   1. 24   1. 63  
earnings avg:  -0. 35   0. 98   1. 51  
earnings low:  -0. 43   0. 73   1. 38  
revenue high:  1. 65 M 2. 84 B 10. 79 B
revenue avg:  880. 00 K 2. 75 B 10. 45 B
revenue low:  370. 00 K 2. 64 B 10. 25 B
return on assets:  -21. 04 % -3. 52 % 3. 78 %
return on equity:  -34. 62 % 105. 21 % 25. 65 %
revenue growth:  -58. 90 % 595. 46 % 90. 55 %
revenue/share:  0. 09   14. 46   58. 94  

beta (1yr vs S&P500):  1. 11   1. 22   0. 94  
sharpe (1yr):  -1. 44   0. 20   1. 02  

held % insiders:  1. 77 % 6. 52 % 3. 28 %
held % institutions:  82. 36 % 79. 51 % 70. 64 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-11 : CMRX
.        + 0 =             0 :: INITIAL WEIGHT
.  + 383.393 =       383.393 :: inverse volume-to-price addition
.  + 430.768 =       814.161 :: spline projection addition
.  - 146.753 =       667.408 :: poor performance penalty
.    x 0.666 =       444.332 :: one-year gains+dividend factor
.    x 2.728 =      1212.243 :: 13 weeks' performance factor
.    x 1.494 =      1810.593 :: industry recommendation factor
.    x 0.998 =      1806.784 :: return on assets factor
.    x 0.997 =      1800.528 :: return on equity factor
.    x 0.994 =      1789.923 :: revenue growth factor
.    x 3.692 =      6608.829 :: current ratio factor
.    x 1.027 =      6784.412 :: quick ratio factor
.    x 1.421 =      9643.435 :: short ratio factor
.    x 2.006 =     19344.948 :: price-to-book factor
.      x 1.0 =     19348.283 :: debt-to-equity factor
.    x 5.513 =    106663.859 :: EBITDA multiple factor
.    x 2.176 =    232142.385 :: P/E weight
.    x 2.209 =    512793.037 :: PE/G factor
.    x 1.574 =    807051.427 :: beta factor
.    x 0.484 =    391009.611 :: sharpe factor
.    x 1.685 =     658807.35 :: target low factor
.    x 1.294 =    852478.506 :: target mean factor
.    x 1.133 =    966142.307 :: target high factor
.    x 1.056 =   1020140.051 :: industry 12-weeks return
.    x 0.917 =    935043.319 :: "drift" penalty 1 days ago
.    x 0.875 =    818591.487 :: "drift" penalty 3 days ago
.      x 1.0 =    818203.972 :: overall "drift" factor
.    x 0.883 =    722619.396 :: largest single-day jump factor
.    x 0.067 =     48400.495 :: low price factor
.      x 1.0 =     48403.314 :: factor hist industry gain for week 06
.   cubeRoot =        36.444 :: reduced for readability
.                     36.444 :: FINAL WEIGHT for NASDAQ:CMRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org